# Pfizer: Phase 3 study closed enrollment, 1078 enrolled (Obesity, Overweight and/or Obesity)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Pfizer |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) |
| NCT ID | NCT07400653 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Obesity; Overweight and/or Obesity; Overweight; Diabetes, Type 2; Type 2 Diabetes |
| Intervention types | drug, other |
| Target enrollment | 1078 |
| Site countries | United States, Argentina, Bulgaria, Canada, Czechia, Germany, Poland, Romania, Slovakia, Spain, United Kingdom |
| Posted | 2026-02-10 |
| Planned start | 2026-02-24 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-13 |
| Last update posted | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 1078 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07400653). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.